# About Tesarx: An Editorial Digest of the Tesamorelin Record

> Tesarx is an independent editorial project publishing summaries of the peer-reviewed tesamorelin literature. Not a clinic, not a vendor — the FDA-approval scope and the off-label boundary, set out plainly.

An independent editorial digest of the peer-reviewed tesamorelin literature — what it is, what it is not, and the exact scope of what the record supports.

## What Tesarx is

Tesarx is an independent editorial project that publishes summaries of the peer-reviewed research literature on tesamorelin. We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science.

The "rx" in the name is editorial framing — a position this publisher occupies relative to the literature, signaling that the focus is the prescription-drug record and its boundaries. It is not a claim that this site prescribes, dispenses, or fills anything. There is no pharmacy, no consultation, and no treatment offered here.

## FDA-approval scope

We treat scope as the first fact, not a footnote. Tesamorelin is FDA-approved (NDA 022505, 2010) only to reduce excess abdominal fat in HIV-infected adults with lipodystrophy [5]. That single indication is the approved use. General or cosmetic weight loss, anti-aging, performance enhancement, non-HIV fatty-liver treatment, and growth-hormone optimization are all off-label and not FDA-approved.

Wherever this site discusses a use outside the approved indication, that boundary is marked. The pivotal efficacy was demonstrated in HIV-positive adults on antiretroviral therapy [1]; generalization beyond that population is mechanistically plausible but not established by large RCTs [12]. Tesamorelin is also prohibited in sport under the WADA Prohibited List (category S2).

## Why tesamorelin is costly

Two practical realities shape access to the approved product: high pharmaceutical cost and injection-only administration. The approved drug is a once-daily subcutaneous injection requiring reconstitution and refrigerated storage [13], and its price has been a recurring point in the access conversation around the compound.

Research-grade material sold for laboratory use is a separate category from the approved finished drug; it lacks the purity and potency oversight of the approved product. This site reports the literature and the record; it does not list, price, or sell anything, and it carries no vendor or purchase information.

## How we handle the evidence

Every quantitative claim on this site maps to a numbered citation in the reference list — a peer-reviewed study, the FDA-approved labeling, or the NIH LiverTox monograph. We lead with what was measured and attribute it to its source. Where the data is precise, we state it precisely; where a question is unsettled, we say so. We do not extrapolate beyond what the studies report, and we do not present research-grade tesamorelin as a medicine to self-administer.

---

Tesarx files the tesamorelin record as a flat, hard-bordered data sheet — every visceral-fat and IGF-1 figure logged straight to its study, the lone HIV-lipodystrophy approval and the off-label edge ruled in plain view; an exposed-document digest, never a clinic, a pharmacy, or a prescription.